Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Company Announcement, Helsinki, 23 December 2024 at 3 PM (EET)
Nexstim Plc: Conversion of stock options 2023A to stock options 2023B and 2023C
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announced on 16 May 2023 the establishment of the 2023A-C stock option plan based on the authorization granted by the Annual General Meeting on 31 March 2023. The stock options of the stock option plan are marked with the symbols 2023A, 2023B, and 2023C.
The Board decided to convert the stock options 2023A held by the company into stock options 2023B and 2023C, so that 8,763 stock options 2023A are converted to class 2023B, and 8,763 stock options 2023A are converted to class 2023C. After the conversion, 229,294 stock options are marked with the symbol 2023A, 255,583 are marked with the symbol 2023B, and 255,583 are marked with the symbol 2023C.
Further information is available on the website www.nexstim.com, or by contacting:
Leena Niemistö, Chair of Board of Directors
+358 9 2727 170
leena.niemisto@nexstim.com
The Company’s Certified Advisor is Carnegie Investment Bank AB (publ).
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com